IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Puma Biotechnology raises 2026 guidance on NERLYNX demand, details alisertib trial timelineAug 6Quarterly updatealisertibneratinib